false--12-29FY20190001110803P2Y1050.98P3MP6MP1Y0.010.013200000003200000001920000001940000001470000001470000000.00393180.0021845301.3200.010.0110000000100000000000P20YP9YP5YP4YP3YP3YP7YP12MP3YP4Y0.440.390.380.290.290.300.01220.02450.02560.00500.01220.01885800056.65P1YP6MP1YP6MP1YP6M16000000P1Y2M4500000047000000 0001110803 2018-12-31 2019-12-29 0001110803 2020-02-07 0001110803 2019-06-28 0001110803 2018-12-30 0001110803 2019-12-29 0001110803 us-gaap:ServiceOtherMember 2018-01-01 2018-12-30 0001110803 2017-01-02 2017-12-31 0001110803 2018-01-01 2018-12-30 0001110803 us-gaap:ServiceOtherMember 2018-12-31 2019-12-29 0001110803 us-gaap:ServiceOtherMember 2017-01-02 2017-12-31 0001110803 us-gaap:ProductMember 2017-01-02 2017-12-31 0001110803 us-gaap:ProductMember 2018-12-31 2019-12-29 0001110803 us-gaap:ProductMember 2018-01-01 2018-12-30 0001110803 us-gaap:RetainedEarningsMember 2019-12-29 0001110803 us-gaap:AdditionalPaidInCapitalMember 2017-01-02 2017-12-31 0001110803 us-gaap:AdditionalPaidInCapitalMember 2019-12-29 0001110803 us-gaap:TreasuryStockMember 2017-01-02 2017-12-31 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001110803 us-gaap:TreasuryStockMember 2017-12-31 0001110803 us-gaap:TreasuryStockMember 2018-12-31 2019-12-29 0001110803 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 2019-12-29 0001110803 us-gaap:RetainedEarningsMember 2017-01-02 0001110803 us-gaap:TreasuryStockMember 2018-12-30 0001110803 us-gaap:AdditionalPaidInCapitalMember 2017-01-02 0001110803 us-gaap:CommonStockMember 2019-12-29 0001110803 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-30 0001110803 us-gaap:NoncontrollingInterestMember 2017-12-31 0001110803 us-gaap:RetainedEarningsMember 2018-01-01 0001110803 us-gaap:RetainedEarningsMember 2018-12-31 2019-12-29 0001110803 us-gaap:RetainedEarningsMember 2017-12-31 0001110803 us-gaap:AdditionalPaidInCapitalMember 2018-12-30 0001110803 us-gaap:TreasuryStockMember 2018-01-01 2018-12-30 0001110803 us-gaap:RetainedEarningsMember 2018-12-31 0001110803 us-gaap:RetainedEarningsMember 2017-01-01 0001110803 us-gaap:TreasuryStockMember 2017-01-01 0001110803 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-30 0001110803 2017-01-01 0001110803 us-gaap:CommonStockMember 2017-01-02 2017-12-31 0001110803 us-gaap:TreasuryStockMember 2019-12-29 0001110803 2018-01-01 0001110803 2018-12-31 0001110803 us-gaap:CommonStockMember 2017-12-31 0001110803 us-gaap:NoncontrollingInterestMember 2018-12-30 0001110803 us-gaap:CommonStockMember 2018-12-30 0001110803 2017-12-31 0001110803 us-gaap:NoncontrollingInterestMember 2018-12-31 2019-12-29 0001110803 us-gaap:CommonStockMember 2017-01-01 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-29 0001110803 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-30 0001110803 2017-01-02 0001110803 us-gaap:NoncontrollingInterestMember 2017-01-02 2017-12-31 0001110803 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001110803 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 0001110803 us-gaap:RetainedEarningsMember 2017-01-02 2017-12-31 0001110803 us-gaap:NoncontrollingInterestMember 2019-12-29 0001110803 us-gaap:RetainedEarningsMember 2018-12-30 0001110803 us-gaap:CommonStockMember 2018-12-31 2019-12-29 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 2019-12-29 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-30 0001110803 us-gaap:CommonStockMember 2018-01-01 2018-12-30 0001110803 us-gaap:NoncontrollingInterestMember 2017-01-01 0001110803 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001110803 2019-01-01 0001110803 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2017-01-02 0001110803 srt:MaximumMember 2019-12-29 0001110803 us-gaap:NonUsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-30 0001110803 us-gaap:InvesteeMember 2017-01-02 2017-12-31 0001110803 us-gaap:InvesteeMember 2018-01-01 2018-12-30 0001110803 ilmn:ConsumablesMember srt:MaximumMember 2018-12-31 2019-12-29 0001110803 srt:MinimumMember 2019-12-29 0001110803 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-12-29 0001110803 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2018-12-31 2019-12-29 0001110803 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-30 0001110803 us-gaap:InvesteeMember 2018-12-31 2019-12-29 0001110803 srt:MaximumMember 2018-12-31 2019-12-29 0001110803 us-gaap:NonUsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2018-12-31 2019-12-29 0001110803 ilmn:InvestmentPortfolioMember ilmn:IndustryCreditConcentrationRiskMember 2018-12-31 2019-12-29 0001110803 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-30 0001110803 us-gaap:NonUsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2017-01-02 2017-12-31 0001110803 ilmn:IssueSizeMember us-gaap:CreditConcentrationRiskMember 2018-12-31 2019-12-29 0001110803 srt:MinimumMember 2018-12-31 2019-12-29 0001110803 ilmn:InvestmentPortfolioMember us-gaap:CreditConcentrationRiskMember 2018-12-31 2019-12-29 0001110803 us-gaap:FurnitureAndFixturesMember 2018-12-31 2019-12-29 0001110803 srt:MinimumMember ilmn:BuildingandLeaseholdImprovementsMember 2018-12-31 2019-12-29 0001110803 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2018-12-31 2019-12-29 0001110803 srt:MaximumMember us-gaap:ComputerEquipmentMember 2018-12-31 2019-12-29 0001110803 srt:MaximumMember ilmn:BuildingandLeaseholdImprovementsMember 2018-12-31 2019-12-29 0001110803 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2018-12-31 2019-12-29 0001110803 srt:MinimumMember us-gaap:ComputerEquipmentMember 2018-12-31 2019-12-29 0001110803 ilmn:InstrumentsMember 2018-12-31 2019-12-29 0001110803 ilmn:ConsumablesMember srt:MinimumMember 2018-12-31 2019-12-29 0001110803 2019-12-29 2019-12-29 0001110803 country:US 2018-12-31 2019-12-29 0001110803 country:US 2018-01-01 2018-12-30 0001110803 2021-01-04 2019-12-29 0001110803 country:US 2017-01-02 2017-12-31 0001110803 us-gaap:EMEAMember 2017-01-02 2017-12-31 0001110803 us-gaap:EMEAMember 2018-12-31 2019-12-29 0001110803 srt:AsiaPacificMember 2018-01-01 2018-12-30 0001110803 country:CN 2018-12-31 2019-12-29 0001110803 srt:AmericasMember 2018-12-31 2019-12-29 0001110803 country:CN 2018-01-01 2018-12-30 0001110803 srt:AsiaPacificMember 2018-12-31 2019-12-29 0001110803 us-gaap:EMEAMember 2018-01-01 2018-12-30 0001110803 srt:AmericasMember 2017-01-02 2017-12-31 0001110803 srt:AmericasMember 2018-01-01 2018-12-30 0001110803 country:CN 2017-01-02 2017-12-31 0001110803 srt:AsiaPacificMember 2017-01-02 2017-12-31 0001110803 us-gaap:ServiceOtherMember ilmn:MicroarrayMember 2017-01-02 2017-12-31 0001110803 ilmn:InstrumentsMember 2018-01-01 2018-12-30 0001110803 ilmn:MicroarrayMember 2018-01-01 2018-12-30 0001110803 ilmn:ConsumablesMember 2017-01-02 2017-12-31 0001110803 ilmn:ConsumablesMember ilmn:MicroarrayMember 2017-01-02 2017-12-31 0001110803 us-gaap:ServiceOtherMember ilmn:SequencingMember 2017-01-02 2017-12-31 0001110803 ilmn:ConsumablesMember ilmn:MicroarrayMember 2018-01-01 2018-12-30 0001110803 ilmn:SequencingMember 2017-01-02 2017-12-31 0001110803 us-gaap:ServiceOtherMember ilmn:SequencingMember 2018-12-31 2019-12-29 0001110803 us-gaap:ServiceOtherMember ilmn:MicroarrayMember 2018-01-01 2018-12-30 0001110803 ilmn:SequencingMember 2018-12-31 2019-12-29 0001110803 ilmn:InstrumentsMember ilmn:SequencingMember 2018-01-01 2018-12-30 0001110803 us-gaap:ProductMember ilmn:SequencingMember 2017-01-02 2017-12-31 0001110803 us-gaap:ProductMember ilmn:SequencingMember 2018-01-01 2018-12-30 0001110803 ilmn:ConsumablesMember ilmn:MicroarrayMember 2018-12-31 2019-12-29 0001110803 us-gaap:ProductMember ilmn:MicroarrayMember 2018-12-31 2019-12-29 0001110803 ilmn:InstrumentsMember ilmn:MicroarrayMember 2018-01-01 2018-12-30 0001110803 ilmn:InstrumentsMember ilmn:MicroarrayMember 2018-12-31 2019-12-29 0001110803 ilmn:SequencingMember 2018-01-01 2018-12-30 0001110803 us-gaap:ProductMember ilmn:MicroarrayMember 2017-01-02 2017-12-31 0001110803 ilmn:InstrumentsMember ilmn:SequencingMember 2017-01-02 2017-12-31 0001110803 ilmn:ConsumablesMember 2018-12-31 2019-12-29 0001110803 us-gaap:ServiceOtherMember ilmn:SequencingMember 2018-01-01 2018-12-30 0001110803 ilmn:InstrumentsMember ilmn:SequencingMember 2018-12-31 2019-12-29 0001110803 ilmn:InstrumentsMember 2017-01-02 2017-12-31 0001110803 us-gaap:ProductMember ilmn:MicroarrayMember 2018-01-01 2018-12-30 0001110803 ilmn:ConsumablesMember ilmn:SequencingMember 2018-12-31 2019-12-29 0001110803 ilmn:MicroarrayMember 2018-12-31 2019-12-29 0001110803 ilmn:MicroarrayMember 2017-01-02 2017-12-31 0001110803 ilmn:InstrumentsMember ilmn:MicroarrayMember 2017-01-02 2017-12-31 0001110803 ilmn:ConsumablesMember ilmn:SequencingMember 2018-01-01 2018-12-30 0001110803 us-gaap:ProductMember ilmn:SequencingMember 2018-12-31 2019-12-29 0001110803 ilmn:ConsumablesMember ilmn:SequencingMember 2017-01-02 2017-12-31 0001110803 us-gaap:ServiceOtherMember ilmn:MicroarrayMember 2018-12-31 2019-12-29 0001110803 ilmn:ConsumablesMember 2018-01-01 2018-12-30 0001110803 us-gaap:USTreasurySecuritiesMember 2018-12-30 0001110803 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:USTreasurySecuritiesMember 2019-12-29 0001110803 us-gaap:CorporateDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:CorporateDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-29 0001110803 us-gaap:FairValueMeasurementsRecurringMember 2018-12-30 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-29 0001110803 us-gaap:FairValueMeasurementsRecurringMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-30 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-30 0001110803 ilmn:HelixHoldingsILLCMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-07-31 0001110803 ilmn:GRAILInc.Member 2017-02-28 2017-02-28 0001110803 ilmn:HelixHoldingsILLCMember 2019-12-29 0001110803 ilmn:SecondVentureCapitalInvestmentFundMember 2019-12-29 0001110803 ilmn:GRAILInc.Member 2017-02-28 0001110803 ilmn:VentureCapitalInvestmentFundtheFundMember 2018-12-31 2019-12-29 0001110803 ilmn:GRAILInc.Member us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-02-28 0001110803 ilmn:HelixHoldingsILLCMember 2019-04-25 2019-04-25 0001110803 ilmn:HelixHoldingsILLCMember 2018-12-31 2019-12-29 0001110803 ilmn:VentureCapitalInvestmentFundtheFundMember 2019-12-29 0001110803 ilmn:HelixHoldingsILLCMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-12-30 0001110803 ilmn:HelixHoldingsILLCMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-01-01 2018-12-30 0001110803 ilmn:HelixHoldingsILLCMember 2019-04-25 0001110803 us-gaap:CustomerRelationshipsMember 2018-12-30 0001110803 us-gaap:LicensingAgreementsMember 2019-12-29 0001110803 us-gaap:DevelopedTechnologyRightsMember 2019-12-29 0001110803 us-gaap:TradeNamesMember 2018-12-30 0001110803 ilmn:LicensedTechnologyMember 2018-12-30 0001110803 ilmn:LicensedTechnologyMember 2019-12-29 0001110803 us-gaap:CustomerRelationshipsMember 2019-12-29 0001110803 us-gaap:LicensingAgreementsMember 2018-12-30 0001110803 us-gaap:TradeNamesMember 2019-12-29 0001110803 us-gaap:DevelopedTechnologyRightsMember 2018-12-30 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember 2019-09-30 2019-12-29 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember us-gaap:SubsequentEventMember 2020-01-02 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-12-31 2019-12-29 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember 2019-12-18 2019-12-18 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember us-gaap:SubsequentEventMember 2020-01-02 2020-01-02 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember 2018-11-01 2018-11-01 0001110803 srt:ScenarioForecastMember ilmn:PacificBiosciencesofCaliforniaIncPacBioMember us-gaap:SubsequentEventMember 2020-01-02 2020-03-02 0001110803 ilmn:EdicoGenomeMember us-gaap:TradeNamesMember 2018-05-14 2018-05-14 0001110803 ilmn:EdicoGenomeMember us-gaap:DevelopedTechnologyRightsMember 2018-05-14 2018-05-14 0001110803 ilmn:EdicoGenomeMember 2018-05-14 2018-05-14 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember 2019-10-01 2019-12-02 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember 2018-11-01 0001110803 us-gaap:InProcessResearchAndDevelopmentMember 2017-01-02 2017-12-31 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember 2019-12-29 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember us-gaap:SubsequentEventMember 2020-02-03 2020-02-03 0001110803 2019-04-01 2019-06-30 0001110803 ilmn:PacificBiosciencesofCaliforniaIncPacBioMember us-gaap:SubsequentEventMember 2020-02-10 2020-03-02 0001110803 ilmn:ConvertibleSeniorNotesDue2019Member 2018-12-31 2019-12-29 0001110803 ilmn:ConvertibleSeniorNotesDue2019Member us-gaap:ConvertibleDebtMember 2018-12-30 0001110803 ilmn:ConvertibleSeniorNotesDue2019Member us-gaap:ConvertibleDebtMember 2019-12-29 0001110803 us-gaap:ConvertibleDebtMember 2018-01-01 2018-12-30 0001110803 us-gaap:ConvertibleDebtMember 2019-12-29 0001110803 ilmn:ConvertibleSeniorNotesDue2021Member us-gaap:ConvertibleDebtMember 2019-12-29 0001110803 us-gaap:ConvertibleDebtMember 2018-12-30 0001110803 ilmn:ConvertibleSeniorNotesDue2023Member us-gaap:ConvertibleDebtMember 2018-12-30 0001110803 ilmn:ConvertibleSeniorNotesDue2021Member us-gaap:ConvertibleDebtMember 2018-12-30 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2019-12-29 0001110803 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2018-12-30 0001110803 ilmn:ConvertibleSeniorNotesDue2023Member us-gaap:ConvertibleDebtMember 2019-12-29 0001110803 us-gaap:ConvertibleDebtMember 2018-12-31 2019-12-29 0001110803 ilmn:ConvertibleSeniorNotesDue2019Member us-gaap:ConvertibleDebtMember 2014-06-29 0001110803 ilmn:ConvertibleSeniorNotesDue2021Member us-gaap:ConvertibleDebtMember 2014-06-01 2014-06-29 0001110803 ilmn:ConvertibleSeniorNotesDue2021Member us-gaap:ConvertibleDebtMember 2014-06-29 0001110803 ilmn:ConvertibleSeniorNotesDue2021Member us-gaap:ConvertibleDebtMember 2018-12-31 2019-12-29 0001110803 ilmn:ConvertibleSeniorNotesDue2023Member us-gaap:ConvertibleDebtMember 2018-08-21 0001110803 ilmn:ConvertibleSeniorNotesDue2019Member us-gaap:ConvertibleDebtMember 2014-06-01 2014-06-29 0001110803 ilmn:ConvertibleSeniorNotesDue2023Member us-gaap:ConvertibleDebtMember 2018-08-21 2018-08-21 0001110803 us-gaap:EmployeeStockMember 2018-01-01 2018-12-30 0001110803 us-gaap:EmployeeStockMember 2017-01-02 2017-12-31 0001110803 us-gaap:EmployeeStockMember 2018-12-31 2019-12-29 0001110803 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-30 0001110803 us-gaap:RestrictedStockUnitsRSUMember 2017-01-02 2017-12-31 0001110803 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 2019-12-29 0001110803 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-30 0001110803 us-gaap:PerformanceSharesMember 2019-12-29 0001110803 us-gaap:PerformanceSharesMember 2017-12-31 0001110803 us-gaap:PerformanceSharesMember 2018-12-30 0001110803 us-gaap:RestrictedStockUnitsRSUMember 2018-12-30 0001110803 us-gaap:PerformanceSharesMember 2017-01-01 0001110803 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 0001110803 us-gaap:PerformanceSharesMember 2017-01-02 2017-12-31 0001110803 us-gaap:PerformanceSharesMember 2018-12-31 2019-12-29 0001110803 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001110803 us-gaap:RestrictedStockUnitsRSUMember 2019-12-29 0001110803 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-30 0001110803 us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-12-29 0001110803 ilmn:CostOfServicesMember 2018-01-01 2018-12-30 0001110803 ilmn:CostOfServicesMember 2017-01-02 2017-12-31 0001110803 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-12-31 2019-12-29 0001110803 ilmn:CostOfGoodsSoldMember 2018-01-01 2018-12-30 0001110803 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-02 2017-12-31 0001110803 ilmn:CostOfGoodsSoldMember 2017-01-02 2017-12-31 0001110803 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-30 0001110803 ilmn:CostOfServicesMember 2018-12-31 2019-12-29 0001110803 ilmn:CostOfGoodsSoldMember 2018-12-31 2019-12-29 0001110803 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-02 2017-12-31 0001110803 us-gaap:EmployeeStockMember ilmn:A2000EmployeeStockPurchasePlanMember 2018-12-31 2019-12-29 0001110803 us-gaap:CommonStockMember 2019-12-29 0001110803 us-gaap:CommonStockMember 2017-01-02 2017-12-31 0001110803 us-gaap:EmployeeStockMember ilmn:A2000EmployeeStockPurchasePlanMember 2018-12-30 0001110803 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-02-05 0001110803 srt:MaximumMember us-gaap:PerformanceSharesMember 2018-12-31 2019-12-29 0001110803 us-gaap:CommonStockMember 2019-02-06 0001110803 us-gaap:EmployeeStockMember ilmn:A2000EmployeeStockPurchasePlanMember 2019-12-29 0001110803 us-gaap:CommonStockMember 2018-12-31 2019-12-29 0001110803 ilmn:ConvertibleSeniorNotesDue2023Member us-gaap:CommonStockMember 2018-01-01 2018-12-30 0001110803 ilmn:A2015StockAndIncentiveCompensationPlanAnd2005SolexaEquityPlanMember 2019-12-29 0001110803 us-gaap:EmployeeStockMember ilmn:A2000EmployeeStockPurchasePlanMember 2017-01-02 2017-12-31 0001110803 us-gaap:CommonStockMember 2018-01-01 2018-12-30 0001110803 us-gaap:EmployeeStockMember ilmn:A2000EmployeeStockPurchasePlanMember 2018-01-01 2018-12-30 0001110803 2019-12-27 0001110803 srt:MaximumMember us-gaap:EmployeeStockMember 2017-01-02 2017-12-31 0001110803 srt:MinimumMember us-gaap:EmployeeStockMember 2018-01-01 2018-12-30 0001110803 srt:MaximumMember us-gaap:EmployeeStockMember 2018-12-31 2019-12-29 0001110803 srt:MinimumMember us-gaap:EmployeeStockMember 2017-01-02 2017-12-31 0001110803 srt:MaximumMember us-gaap:EmployeeStockMember 2018-01-01 2018-12-30 0001110803 srt:MinimumMember us-gaap:EmployeeStockMember 2018-12-31 2019-12-29 0001110803 ilmn:ConstructionInProgressAndBuildtoSuitLeaseLiabilityMember 2018-01-01 2018-12-30 0001110803 ilmn:ConstructionInProgressAndBuildtoSuitLeaseLiabilityMember 2017-01-02 2017-12-31 0001110803 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-30 0001110803 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-29 0001110803 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-29 0001110803 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-30 0001110803 us-gaap:BuildingMember 2019-12-29 0001110803 us-gaap:FurnitureAndFixturesMember 2018-12-30 0001110803 us-gaap:FurnitureAndFixturesMember 2019-12-29 0001110803 us-gaap:ComputerEquipmentMember 2018-12-30 0001110803 us-gaap:ComputerEquipmentMember 2019-12-29 0001110803 us-gaap:BuildingMember 2018-12-30 0001110803 us-gaap:LeaseholdImprovementsMember 2018-12-30 0001110803 us-gaap:ConstructionInProgressMember 2018-12-30 0001110803 us-gaap:ConstructionInProgressMember 2019-12-29 0001110803 us-gaap:EquipmentMember 2019-12-29 0001110803 us-gaap:LeaseholdImprovementsMember 2019-12-29 0001110803 us-gaap:EquipmentMember 2018-12-30 0001110803 us-gaap:ForeignCountryMember us-gaap:InlandRevenueSingaporeIRASMember 2018-12-31 2019-12-29 0001110803 us-gaap:StateAndLocalJurisdictionMember 2019-12-29 0001110803 us-gaap:ForeignCountryMember us-gaap:InlandRevenueSingaporeIRASMember 2017-01-02 2017-12-31 0001110803 us-gaap:ForeignCountryMember us-gaap:InlandRevenueSingaporeIRASMember 2018-01-01 2018-12-30 0001110803 us-gaap:ForeignCountryMember us-gaap:HerMajestysRevenueAndCustomsHMRCMember 2018-12-31 2019-12-29 0001110803 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2019-12-29 0001110803 us-gaap:TaxYear2017Member 2019-12-29 0001110803 us-gaap:DeferredCompensationExcludingShareBasedPaymentsAndRetirementBenefitsMember 2018-12-30 0001110803 ilmn:SeniorLevelEmployeeMember us-gaap:DeferredCompensationExcludingShareBasedPaymentsAndRetirementBenefitsMember 2018-12-31 2019-12-29 0001110803 us-gaap:DeferredCompensationExcludingShareBasedPaymentsAndRetirementBenefitsMember 2019-12-29 0001110803 us-gaap:DeferredCompensationExcludingShareBasedPaymentsAndRetirementBenefitsMember 2018-12-31 2019-12-29 0001110803 srt:DirectorMember us-gaap:DeferredCompensationExcludingShareBasedPaymentsAndRetirementBenefitsMember 2018-12-31 2019-12-29 0001110803 country:GB 2018-12-30 0001110803 country:GB 2019-12-29 0001110803 country:US 2019-12-29 0001110803 country:US 2018-12-30 0001110803 ilmn:OtherCountriesMember 2019-12-29 0001110803 country:SG 2018-12-30 0001110803 country:SG 2019-12-29 0001110803 ilmn:OtherCountriesMember 2018-12-30 0001110803 us-gaap:OperatingSegmentsMember ilmn:CoreIlluminaMember 2019-12-29 0001110803 ilmn:CoreIlluminaMember 2018-01-01 2018-12-30 0001110803 us-gaap:OperatingSegmentsMember ilmn:CoreIlluminaMember 2017-12-31 0001110803 us-gaap:IntersegmentEliminationMember 2018-12-30 0001110803 us-gaap:OperatingSegmentsMember ilmn:ConsolidatedVariableInterestEntitiesMember 2019-12-29 0001110803 ilmn:ConsolidatedVariableInterestEntitiesMember 2017-01-02 2017-12-31 0001110803 us-gaap:OperatingSegmentsMember ilmn:CoreIlluminaMember 2018-12-30 0001110803 us-gaap:IntersegmentEliminationMember 2017-12-31 0001110803 ilmn:ConsolidatedVariableInterestEntitiesMember 2018-12-31 2019-12-29 0001110803 ilmn:CoreIlluminaMember 2018-12-31 2019-12-29 0001110803 us-gaap:OperatingSegmentsMember ilmn:ConsolidatedVariableInterestEntitiesMember 2017-12-31 0001110803 us-gaap:OperatingSegmentsMember ilmn:ConsolidatedVariableInterestEntitiesMember 2018-12-30 0001110803 ilmn:ConsolidatedVariableInterestEntitiesMember 2018-01-01 2018-12-30 0001110803 us-gaap:IntersegmentEliminationMember 2019-12-29 0001110803 ilmn:CoreIlluminaMember 2017-01-02 2017-12-31 0001110803 us-gaap:IntersegmentEliminationMember 2018-12-31 2019-12-29 0001110803 us-gaap:IntersegmentEliminationMember 2017-01-02 2017-12-31 0001110803 us-gaap:OperatingSegmentsMember ilmn:CoreIlluminaMember 2017-01-02 2017-12-31 0001110803 us-gaap:OperatingSegmentsMember ilmn:CoreIlluminaMember 2018-12-31 2019-12-29 0001110803 us-gaap:OperatingSegmentsMember ilmn:ConsolidatedVariableInterestEntitiesMember 2018-01-01 2018-12-30 0001110803 us-gaap:OperatingSegmentsMember ilmn:ConsolidatedVariableInterestEntitiesMember 2017-01-02 2017-12-31 0001110803 us-gaap:OperatingSegmentsMember ilmn:CoreIlluminaMember 2018-01-01 2018-12-30 0001110803 us-gaap:OperatingSegmentsMember ilmn:ConsolidatedVariableInterestEntitiesMember 2018-12-31 2019-12-29 0001110803 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-12-30 0001110803 2018-04-02 2018-07-01 0001110803 2019-09-30 2019-12-29 0001110803 2018-12-31 2019-03-31 0001110803 2019-07-01 2019-09-29 0001110803 2018-10-01 2018-12-30 0001110803 2018-01-01 2018-04-01 0001110803 2018-07-02 2018-09-30 xbrli:pure iso4217:USD xbrli:shares xbrli:shares ilmn:venture utreg:sqft iso4217:USD ilmn:day ilmn:segments

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

For the fiscal year ended December 29, 2019

or

Commission file number: 001-35406

Illumina, Inc.

(Exact name of registrant as specified in its charter)

200 Illumina Way, San Diego, CA 92122

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (858) 202-4500

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes þ     No o

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes o     No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ     No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐    No þ

As of February 7, 2020, there were 147 million shares (excluding 47 million shares held in treasury) of the registrant’s common stock outstanding. The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2019 (the last business day of the registrant’s most recently completed second fiscal quarter), based on the closing price for the common stock on The NASDAQ Global Select Market on June 28, 2019 (the last trading day before June 30, 2019), was $48.2 billion. This amount excludes an aggregate of approximately 17 million shares of common stock held by officers and directors and each person known by the registrant to own 10% or more of the outstanding common stock. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that the registrant is controlled by or under common control with such person.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement for the 2020 annual meeting of stockholders are incorporated by reference into Items 10 through 14 of Part III of this Report

ILLUMINA, INC.

FORM 10-K

FOR THE FISCAL YEAR ENDED DECEMBER 29, 2019

TABLE OF CONTENTS

See “Form 10-K Cross-Reference Index” within Other Key Information for a cross-reference to the parts and items requirements of the Securities and Exchange Commission Annual Report on Form 10-K.

Special Note Regarding Forward-Looking Statements

This annual report on Form 10-K contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” or the negative of these terms, and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding:

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

Any forward-looking statement made by us in this annual report on Form 10-K is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation, and do not intend, to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, or to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of any current financial quarter, in each case whether as a result of new information, future developments, or otherwise.

Available Information

Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports are available free of charge on our website, www.illumina.com. The information on our website is not incorporated by reference into this report. Such reports are made available as soon as reasonably practicable after filing with, or furnishing to, the SEC. The SEC also maintains an Internet site at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that electronically file with the SEC. Copies of our annual report on Form 10-K will be made available, free of charge, upon written request.

_______________________________________

Illumina, 24sure, Ampligase, Assign, BaseSpace, BlueFish, BlueFuse, BlueGnome, Clarity LIMS, CSPro, CytoSeq, DesignStudio, DRAGEN, Durascript, Genetic Energy, GenomeStudio, Globin-Zero, GoldenGate, HiSeq, iSeq, iHope, Illumina Propel Certified, IllumiNotes, Infinium, iScan, iSelect, MiniSeq, MiSeq, MiSeqDx, NextBio, Nextera, NextSeq, NovaSeq, Powered by Illumina, Ribo-Zero, SeqMonitor, SureCell, TruGenome, TruSeq, TruSight, Understand Your Genome, UYG, Verifi, Verinata, Verinata Health, VeriSeq, the pumpkin orange color, and the Genetic Energy streaming bases design are trademarks or registered trademarks of Illumina, Inc.

_______________________________________

Unless the context requires otherwise, references in this annual report on Form 10-K to “Illumina,” the “Company,” “we,” “us,” and “our” refer to Illumina, Inc. and its subsidiaries.

_______________________________________

Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. References to 2019, 2018, and 2017 refer to fiscal years ended December 29, 2019, December 30, 2018, and December 31, 2017, respectively, all of which were 52 weeks.

BUSINESS OVERVIEW

We are the global leader in sequencing- and array-based solutions for genetic and genomic analysis. Our products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. We were incorporated in California in April 1998 and reincorporated in Delaware in July 2000. Our principal executive offices are located at 5200 Illumina Way, San Diego, California 92122. Our telephone number is (858) 202-4500.

Our customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

Our portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. This portfolio addresses the range of genomic complexity, price points, and throughput, enabling customers to select the best solution for their research or clinical application.

Genetics Primer

The instruction set for all living cells is encoded in deoxyribonucleic acid, or DNA. The complete set of DNA for any organism is referred to as its genome. DNA contains small regions called genes, which comprise a string of nucleotide bases labeled A, C, G, and T, representing adenine, cytosine, guanine, and thymine, respectively. These nucleotide bases occur in a precise order known as the DNA sequence. When a gene is “expressed,” a copy of a portion of its DNA sequence called messenger RNA (mRNA) is used as a template to direct the synthesis of a particular protein. Proteins, in turn, direct all cellular function. The illustration below is a simplified gene expression schematic.

Variations among organisms are due, in large part, to differences in their DNA sequences. Changes can result from insertions, deletions, inversions, translocations, or duplications of nucleotide bases. These changes may result in certain genes becoming overexpressed (excessive protein production), underexpressed (reduced protein production), or silenced altogether, sometimes triggering changes in cellular function. The most common form of variation in humans is called a single nucleotide polymorphism (SNP), which is a base change in a single position in a DNA sequence. Another type of variation, copy number variations (CNVs), occur when there are fewer or more copies of certain genes, segments of a gene, or stretches of DNA.

In humans, genetic variation accounts for many of the physical differences we see (e.g., height, hair, eye color, etc.). Genetic variations also can have medical consequences affecting disease susceptibility, including predisposition to complex genetic diseases such as cancer, diabetes, cardiovascular disease, and Alzheimer’s disease. They can affect individuals’ response to certain drug treatments, causing them to respond well, experience adverse side effects, or not respond at all.

Scientists are studying these variations and their consequences in humans, as well as in a broad range of animals, plants, and microorganisms. Such research takes place in government, university, pharmaceutical, biotechnology, and agrigenomics laboratories around the world, where scientists expand our knowledge of the biological functions essential for life. Beginning at the genetic level, our tools are used to elucidate the relationship between gene sequence and biological processes. Researchers who investigate human and non-human genetic variation to understand the mechanisms of disease are enabling the development of more effective diagnostics and therapeutics. They also provide greater insight into genetic variation in plants (e.g., food and biofuel crops) and animals (e.g., livestock and domestic), enabling improvements in crop yields and animal breeding programs.

By empowering genetic analysis and facilitating a deeper understanding of genetic variation and function, our tools advance disease research, drug development, and the creation of molecular diagnostic tests. We believe that this will trigger a fundamental shift in the practice of medicine and health care, and that the increased emphasis on preventive and predictive molecular medicine will usher in the era of precision health care.

Our Principal Markets

We target the markets and customers outlined below.

Life Sciences

Historically, our core business has been in the life sciences research market. This includes laboratories associated with universities, research centers, and government institutions, along with biotechnology and pharmaceutical companies. Researchers at these institutions use our products and services for basic and translational research across a spectrum of scientific applications, including targeted, exome, and whole-genome sequencing; genetic variation; gene expression; epigenetics; and metagenomics. Next-generation sequencing (NGS) technologies are being adopted due to their ability to cost-effectively sequence large sample sizes quickly and accurately, generating vast amounts of high-quality data. Both private and public funding drive this research, along with global initiatives to characterize genetic variation.

Our products also serve various applied markets including consumer genomics and agrigenomics. For example, in consumer genomics, our customers use our technologies to provide personalized genetic data and analysis to individual consumers. In agrigenomics, government and corporate researchers use our products and services to explore the genetic and biological basis for productivity and nutritional constitution in crops and livestock. Researchers can identify natural and novel genomic variation and deploy genome-wide marker-based applications to accelerate breeding and production of healthier and higher-yielding crops and livestock.

Clinical Genomics

We are focused on enabling translational and clinical markets through the introduction of best-in-class sequencing technology. Further, we are developing sample-to-answer solutions to catalyze adoption in the clinical setting, including in reproductive and genetic health and oncology. In reproductive health, our primary focus is driving noninvasive prenatal testing (NIPT) adoption globally through our technology, which identifies fetal chromosomal abnormalities by analyzing cell-free DNA in maternal blood. Our NGS technology is also accelerating rare and undiagnosed disease research to discover the genetic causes of inherited disorders by assessing many genes simultaneously. Using NGS can reduce costs compared to traditional methods of disease diagnosis, which are often expensive and inconclusive while requiring extensive testing.

Cancer is a disease of the genome, and the goal of cancer genomics is to identify genomic changes that transform a normal cell into a cancerous one. Understanding these genomic changes will improve diagnostic accuracy, increase understanding of the prognosis, and enable oncologists to target therapies to individuals. Customers in the translational and clinical oncology markets use our products to perform research that may help identify individuals who are genetically predisposed to cancer and to identify molecular changes in a tumor. We believe that circulating tumor DNA (ctDNA) will become an important clinical tool for managing oncology patients during all stages of tumor progression. Our technology is being used to research the implications of ctDNA in treatment determination, treatment monitoring, minimal residual disease, and asymptomatic screening. For example, we have invested in, and partnered with GRAIL, which we formed to develop a blood-based test for early-stage cancer detection that is enabled by our sequencing technology.

Our Principal Products, Services, and Technologies

Our unique technology platforms support the scale of experimentation necessary for population-scale studies, genome-wide discovery, target selection, and validation studies (see Figure 1 below). Customers use our products to analyze the genome at all levels of complexity, from targeted panels to whole-genome sequencing. A large and dynamic Illumina user community has published tens of thousands of customer-authored scientific papers using our technologies. Through rapid innovation, we are changing the economics of genetic research, enabling projects that were previously considered impossible, and supporting clinical advances towards precision medicine.

Most of our product sales consist of instruments and consumables, which include reagents, flow cells, and microarrays, based on our proprietary technologies. We also perform various services for our customers. In 2019, 2018, and 2017, instrument sales represented 15%, 17%, and 19%, respectively, of total revenue; consumable sales represented 68%, 65%, and 64%, respectively, of total revenue; and services represented 17%, 18%, and 17%, respectively, of total revenue.

Figure 1: Illumina Platform Overview:

Sequencing

DNA sequencing is the process of determining the order of nucleotide bases (A, C, G, or T) in a DNA sample. Our portfolio of sequencing platforms represents a family of systems that we believe set the standard for productivity, cost-effectiveness, and accuracy among NGS technologies. Customers use our platforms to perform whole-genome, de novo, exome and RNA sequencing, and targeted resequencing of specific gene regions and genes.

Whole-genome sequencing determines the complete DNA sequence of an organism. In de novo sequencing, the goal is to sequence and assemble the genome of that sample without using information from prior sequencing of that species. In targeted resequencing, a portion of the sequence of an organism is compared to a standard or reference sequence from previously sequenced samples to identify genetic variation. Understanding the similarities and differences in DNA sequence between and within species helps us understand the function of the structures encoded in the DNA.

Our DNA sequencing technology is based on our proprietary reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis (SBS) biochemistry. SBS tracks the addition of labeled nucleotides as the DNA chain is copied in a massively parallel fashion. Our SBS sequencing technology provides researchers with a broad range of applications and the ability to sequence even large mammalian genomes in a few days rather than weeks or years.

Our sequencing platforms can generate between 500 megabases (Mb) and 6.0 terabases (Tb) (equivalent to approximately 48 human genomes) of genomic data in a single run, depending on the instrument and application.

There are different price points per gigabase (Gb) for each instrument, and for different applications, which range from small-genome, amplicon, and targeted gene-panel sequencing to population-scale whole human genome sequencing. Since we launched our first sequencing system in 2007, our systems have reduced the cost of sequencing by a factor of more than 10,000. In addition, the sequencing time per Gb has dropped by a factor of approximately 12,000.

Our BaseSpace Informatics Suite cloud platform plays a critical role in supporting our sequencing applications. BaseSpace Informatics Suite integrates directly with our sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive meaningful results.  It facilitates data sharing, provides data-storage solutions and streamlines analysis through a growing number of applications developed by us and the bioinformatics community.

In 2019, 2018, and 2017, total sequencing revenue comprised 87%, 83%, and 83%, respectively, of total revenue.

Arrays

Arrays are used for a broad range of DNA and RNA analysis applications, including SNP genotyping, CNV analysis, gene expression analysis, and methylation analysis, and enable the detection of millions of known genetic markers on a single array. Arrays are the primary technology used in consumer genomics applications.

Our BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform many assays simultaneously. This facilitates large-scale analysis of genetic variation and biological function in a unique, high-throughput, cost-effective, and flexible manner. Using our BeadArray technology, we achieve high-throughput analysis via a high density of test sites per array and the ability to format arrays in various configurations. To serve the needs of multiple markets and market segments, we can vary the size, shape, and format of the substrate into which the beads self-assemble and create specific bead types for different applications. Our iScan System and our NextSeq 550 System can be used to image arrays.

In 2019, 2018, and 2017, total array revenue comprised 13%, 17%, and 17%, respectively, of total revenue.

Consumables

We have developed various library preparation and sequencing kits to simplify workflows and accelerate analysis. Our sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Our sequencing kits maximize the ability of our customers to characterize the target genome accurately and are sold in various configurations, addressing a wide range of applications.

Customers use our array-based genotyping consumables for a wide range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer. Customers can select from a range of human, animal, and agriculturally relevant genome panels or create their own custom arrays to investigate millions of genetic markers targeting any species.

Services

We provide whole-genome sequencing, genotyping, NIPT, and product support services. Human whole-genome sequencing services are provided through our CLIA-certified, CAP-accredited laboratory. Using our services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). We also provide NIPT services through our partner laboratories that direct samples to us on a test send-out basis in our CLIA-certified, CAP-accredited laboratory. In addition, we also offer support services to customers who have purchased our products.

Intellectual Property

We have an extensive intellectual property portfolio. As of January 16, 2020, we owned or had exclusive licenses to 799 issued U.S. patents and 617 pending U.S. patent applications, including 61 allowed applications that have not yet issued as patents. Our issued and pending patents cover various aspects of our arrays, assays, oligo synthesis, sequencing technology, instruments, digital microfluidics, software, bioinformatics, and chemical-detection technologies, and have terms that expire between 2020 and 2040. We continue to file new patent applications to protect the full range of our technologies. We have filed or have been granted counterparts for many of these patents and applications in foreign countries.

We protect our trade secrets, know-how, copyrights, and trademarks. Our success depends in part on obtaining patent protection for our products and processes, preserving trade secrets, patents, obtaining copyrights and trademarks, operating without infringing the proprietary rights of third parties, and acquiring licenses for technology or products. In addition, we invest in technological innovation, and we seek beneficial licensing opportunities to develop and maintain our competitive position.

We are party to various exclusive and nonexclusive license agreements and other arrangements with third parties that grant us rights to use key aspects of our sequencing and array technologies, assay methods, chemical detection methods, reagent kits, and scanning equipment. We have additional nonexclusive license agreements with various third parties for other components of our products. In most cases, the agreements remain in effect over the term of the underlying patents, may be terminated at our request without further obligation, and require that we pay customary royalties.

Research and Development

We have historically made substantial investments in research and development. Our research and development efforts prioritize continuous innovation coupled with product evolution.

Research and development expense in 2019, 2018, and 2017 was $647 million, $623 million, and $546 million, respectively. We expect research and development expense to increase during 2020 to support business growth and continuing expansion in research and product-development efforts.

Marketing and Distribution

We market and distribute our products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region. In addition, we sell through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. We expect to continue increasing our sales and distribution resources during 2020 and beyond as we launch new products and expand our potential customer base.

Manufacturing

We manufacture sequencing and array platforms and reagent kits. In 2019, we continued to increase our manufacturing capacity to meet customer demand. To address increasing product complexity and volume, we continue to automate manufacturing processes to accelerate throughput and improve quality and yield. We are committed to providing medical devices and related services that consistently meet customer and applicable regulatory requirements. We adhere to access and safety standards required by federal, state, and local health ordinances, such as standards for the use, handling, and disposal of hazardous substances. Our key manufacturing and distribution facilities operate under a quality management system certified to ISO 13485.

Raw Materials

Our manufacturing operations require a wide variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. Multiple commercial sources provide many of our components and supplies, but there are some raw materials and components that we obtain from single-source suppliers. To manage potential risks arising from single-source suppliers, we believe that, if necessary, we could redesign our products using alternative components or for use with alternative reagents or develop an internal supply capability. In addition, while we attempt to keep our inventory at minimal levels, we purchase incremental inventory as circumstances warrant to protect our supply chain. If the capabilities of our suppliers and component

manufacturers are limited or stopped, due to disasters, quality, regulatory, or other reasons, it could negatively impact our ability to manufacture our products.

  

Competition

Although we believe that our products and services provide significant advantages over products and services currently available from other sources, we expect continued intense competition. Our competitors offer products and services for sequencing, SNP genotyping, gene expression, and molecular diagnostics markets. In some cases, we compete for the resources our customers allocate for purchasing a wide range of sequencing and non-sequencing products used to analyze genetic variation and biological function, some of which are complementary or adjacent to our own but not directly competitive; in other cases, our products face direct competition as customers choose among sequencing and non-sequencing products that are designed to address the same use case or answer the same biological question. Some of our competitors have, or will have, substantially greater financial, technical, research, and other resources than we do, along with larger, more established marketing, sales, distribution, and service organizations. In addition, they may have greater name recognition than we do in the markets we address, and in some cases a larger installed base of systems. We expect new competitors to emerge and the intensity of competition to increase. To compete effectively, we must scale our organization and infrastructure appropriately and demonstrate that our products have superior throughput, cost, and accuracy.

Segment and Geographic Information

We have one reportable segment, Core Illumina, which relates to Illumina’s core operations. Prior to the Helix deconsolidation on April 25, 2019, our reportable segments included both Core Illumina and Helix. Prior to the deconsolidation of GRAIL on February 28, 2017, our Consolidated VIEs reportable segment included the combined operations of Helix and GRAIL.

We currently sell our products to a number of customers outside the United States, including customers in other areas of North America, Latin America, Europe, China, and the Asia-Pacific region. Shipments to customers outside the United States totaled $1,684 million, or 48%, of total revenue, in 2019, compared to $1,554 million, or 47%, and $1,241 million, or 45%, in 2018 and 2017, respectively. We consider the U.S. dollar to be the functional currency of our international operations due to the primary activities of our foreign subsidiaries. We expect that sales to international customers will continue to be an important and growing source of revenue. See note “1. Organization and Significant Accounting Policies” and note “2. Revenue” within the Consolidated Financial Statements section of this report for further information concerning our foreign and domestic operations.

Backlog

Our backlog was approximately $980 million and $909 million as of December 29, 2019 and December 30, 2018, respectively. Generally, our backlog consists of orders believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions as we launch new products. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters, and whether the product is catalog or custom. We expect approximately 66% of our backlog as of December 29, 2019, to be shipped in 2020, approximately 14% in 2021, and the remainder thereafter. Although we generally recognize revenue when control of our products and services is transferred to our customers, some customer contracts might require us to defer revenue recognition beyond the transfer of control.